What was the purpose of the study by Adeoye et al. on Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke?
The purpose of the study by Adeoye et al. was to explore the efficacy of a combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke, with the aim of determining if this approach could improve outcomes compared to the use of recombinant tissue-type plasminogen activator alone. This was accomplished through a propensity score-matched post hoc analysis of data from the Full Dose Regimen Stroke Trial. The study concluded that the combined approach of eptifibatide and recombinant tissue-type plasminogen activator was associated with a higher rate of favorable neurological outcome than the use of recombinant tissue-type plasminogen activator alone.  